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Targeted removal of blood cancer cells from mixed cell 
populations by cell recognition with matching particle imprints 
Perrine Remaud,a Jevan Medlocka, Anupam A. K. Dasa, David J. Allsupb, Leigh A. Maddenc,  
Dieter Nees,d Paul J. Weldricka and Vesselin N. Paunova* 
We report a new approach for separation of blood cancer cells from healthy white blood cells based on cell recognition by 
surface functionalised particle imprints. We prepared polymeric particle imprints from a layer of suspension of 
monodisperse PMMA microbeads which closely match the size of in-vitro cultured human leukaemia cells (HL60). The 
imprints were replicated on a large scale with UV curable polyurethane resin using Nanoimprinting lithography and surface 
functionalized with a cationic polymer, branched polyethylene imine (bPEI) and a Pluronic surfactant, Poloxamer 407, to 
exert a weak attraction towards the cells. The latter is amplified several orders of magnitude when a cell of closely matching 
size and shape fits into the imprint cavity which multiplies the contact area between cell surface and the imprint cavity. The 
particle imprints were optimised for their specificity toward the blood cancer cells by treatment with oxygen plasma and 
then subsequent coatings with bPEI and Poloxamer 407 with various functionalisation concentrations. We tested the surface 
functionalised imprints for their specificity in retaining in vitro cultured human leukaemic cells  (HL60) over healthy human 
peripheral blood mononuclear cells (PBMCs) in a flow through chamber. The effect of the flushing flow rate of over the 
mixed cell solution suspension over the particle imprint and the particle imprint length were also investigated. At each step 
the selectivity towards HL60 was assessed. Selective isolation of an increased amount of HL60 tumour cells over PBMC was 
ultimately achieved as a function of cell seeding ratio on the particle imprint. The effect is attributed to the substantial size 
difference between the HL60 cell and the PBMCs. The data presented show that relatively inexpensive PMMA microbeads 
imprints can be utilised as a cell separation technique which could ultimately lead to novel therapies for removal of the 
neoplastic cells from peripheral blood of acute myeloid leukaemia patients. 
Introduction 
Bioimprints are polymeric replicas of cells or microorganisms 
which produce surface cavities of the same shape and size as 
the original cells.1,2 These polymer based cavities then can be 
optimised to allow specific recognition of the target cells of 
matching size and shape. The bioimprint acts in the same 
principle as that of the Lock and Key model which enables the 
shape and size based recognition of specific cells.1,3-5  The first 
report of bioimprints is credited to Dickert et al.6 who created a 
highly selective yeast imprint from a sol-gel matrix. Further 
whole cell imprints have been made from a range of micro-
organisms and human cells. As utilised here, Hayden et al.7 
functionalised red blood cell polyurethane imprints capable of 
distinguishing cells via blood group antigen recognition. 
Subsequently they were able to separate cells from blood 
groups A1 and A2.8 Molecular imprinted polymers have also 
been utilised for biological applications such as bacteria, virus 
and chemical sensing. 9-11 The advantages of imprinting 
technologies lie in their ease of manufacture, stability, 
reusability and importantly, specificity for biological targets. 12 
Acute myeloid leukaemia (AML) presents as uncontrolled 
proliferation of neoplastic cells (myeloblasts) causing an 
imbalance in haematopoiesis leading to bone marrow failure 
and resulting in a death of the patient if untreated.13-15 In the 
UK, the average overall 5-year survival is 16% from the point of 
diagnosis. The prognosis is significantly worse in the majority of 
patients due to disease presentation in the later years of 
life.13,16-19 Current AML treatment is myeloablative 
chemotherapy followed by an allogeneic stem cell transplant.20-
21 AML patients spend a long time hospitalised and suffer 
considerable morbidity related to anaemia, sepsis and bleeding. 
Outcomes for AML patients have only improved in relation to 
supportive care pathways rather than any new drug regimens.22 
There is an urgent need to seek alternative therapies for these 
patients. Selective leukophoresis can potentially be used more 
in the extraction of myeloblasts from peripheral blood which is 
critical in stabilizing AML patients with leukostasis associated 
with hyperleuocytosis.23 By reducing the number of circulating 
tumour cells, the likelihood of early relapse is also diminished.24  
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Figure 1. The principle of particle imprint-based AML cell depletion from a mixture with 
PBMCs. The substantially larger (AML) cells are preferentially attracted and retained on 
the imprint due to large contact area whereas smaller, healthy PBMCs are flushed 
through with little interaction. 
 
AML blood cancer cells present an ideal target for cell shape 
recognition by prefabricated bioimprinted surfaces where a 
very strong specific adhesion can occur between the imprinted 
cell surface pattern and the cells of matching shape. The 
separation between the myeloblasts and healthy white blood 
cells on a particle imprint should occur due to the distinct cell 
size and morphological differences between the myeloblasts 
and normal blood cells (Figure 1). The cell surfaces are normally 
negatively charged due to the presence of integral proteins and 
carbohydrates with negatively charged COO- groups on the 
phospholipid bilayer.25 Hence, the imprints can be first treated 
with a biocompatible cationic polyelectrolyte to promote 
attractive electrostatic interaction between the target cells and 
the imprint surface. The polymeric imprints can be potentially 
used for various applications in different fields due to their low 
production cost, unique mechanical, thermal and chemical 
properties, their stability and their ease to be prepared.26 The 
molecular imprinting technology has been used in many 
different areas such as separation methods, biosensors, organic 
synthesis and drug development.27 This imprinting technology 
also has great prospects in the field of biomedicine hence, this 
study is aimed at the development of matching  imprints for 
medical applications such as a supplementary therapy for blood 
cancer that can be used alongside conventional chemotherapy. 
There are two types of methods to create imprinted polymers28 
the cell-membrane-molecular imprinting and the whole-cell-
imprinting strategy. The former use only a part of the cell 
surface while the second method replicates the cells as a whole 
entities or constituent bio-macromolecules. We have recently 
utilised a bioimprinting approach to remove tumour cells from 
healthy cells.29  This approach, whilst successful would be time 
consuming to replicate for individual patients where a 
bioimprint must be made from the individuals tumour cells, 
which would first have to be isolated from whole blood. A 
simple particle imprint of matching target cell size could simplify 
this approach and negate the requirement for individualised 
bioimprints. However, casting cells with polymers opens a range 
of challenges as the cells can potentially shrink, flatten and 
change their shape during the replication process due to drying 
or upon contact with the resins. In this project, a novel 
imprinting strategy using monodisperse 
poly(methylmethacrylate) (PMMA) microbeads of a similar size 
to target blood cancer cells (~14 m) was used to mimic the 
whole cell bioimprinting. The strategy is reminiscent of the 
method used to fabricate micro-lenses arrays by dual 
templating of monodisperse particle monolayers with PDMS 
and UV-curable optical adhesive.40 Its application produced a 
positive imprint a microbeads layer imprint which could then be 
upscaled using the Roll-to Roll-nanolithography method (R2R 
NIL).30 In order to increase the selectivity of the particle imprint 
towards the blood cancer cells the particle imprint was first 
treated with the cationic polyelectrolyte bPEI in order to 
promote attractive electrostatic interaction between the target 
cells and the particle imprint surface. In order to weaken the 
attraction and make the interaction cell-imprint more specific 
with respect to the cell shape and size, a secondary treatment 
in the form of POL407 was used to passivate the surface of the 
positively charged particle imprint in order to make healthy 
white blood cells less likely to non-specifically attach to the 
imprint. Hence the interaction needs to be weak enough to rely 
on the amplification of the contact area between the cells and 
the imprint cavities surface. The function of the POL407 is to 
offset the approaching cells from imprint which weakens the 
attraction. This is needed to reduce the non-specific adhesion 
of the PBMCs with the imprint upon point contact, while 
magnifying the interaction between HL60 cells and the imprint 
cavities. The particle imprint used for this specific study was 
made using 15 m PMMA microbeads (Spheromers CA15, 
Microbeads) (Fig. 2) which have matching size to the targeted 
HL60 cells of average diameter of 14 µm (See Figure S1, ESI). 
Materials and Methods 
Preparation of CA15 particle imprints 
Spheromers C15 microbeads were sourced from Microbeads AS, 
Norway (www.micro-beads.com). Glass substrates (70 cm  40 cm) 
were cleaned with acetone and alcoholic KOH (10 wt%) for 1 h, 
washed with deionized water and treated with 20 wt% 
poly(diallyldimethylammonium chloride)  (PDAC) aqueous solution 
for 30 min, followed by further cleaning with deionized water drying 
under air stream. A sample of 6.0 g of Spheromers CA15 PMMA 
microbeads, 2.5 g of glucose was mixed together in 30 mL of 0.1% 
(w/v) % xanthan gum solution. Spreading of this CA15 suspension on 
the glass substrate was done using a glass tool comprised of a square 
frame of four glass strips, one of which was offset by 100 µm to 
create a gap. The CA15 suspension was added to the frame cavity 
and the tool was moved over the glass substrate (with a lead) in a 
steady motion in the direction opposite to the higher side. This 
allowed an aqueous film of CA15 microbeads suspension (40 cm  70 
cm) of uniform thickness (~100 m) to be deposited, followed by 
evaporation to a semi-dry state at room temperature in a laminar 
flow cabinet. Curable Sylgard 184 elastomer (polydymetylsiloxane, 
PDMS, from Dow Corning) was mixed at a 10:1 ratio of elastomer to 
accelerator and degassed by 10 min centrifugation at 4000g. A metal 
frame of interior space 65304 cm was placed on top of the 
produced CA15 microbeads layer and the PDMS elastomer solution 
(900 mL) was poured evenly inside.  
 
Materials Chemistry Frontiers  ARTICLE 





Figure 2. The process of imprint production from PMMA microbeads layers. CA15 PMMA particles were formulated as an aqueous suspension containing 
glucose and spread evenly over a glass substrate. The produced microbeads layer was levelled off with a bespoke tool and dried up in air. The microbeads 
layer was casted with curable silicone (PDMS). The latter was peeled off after 24 h of curing and cleaned up to make a negative imprint. This imprint was 
casted a second time with UV-curable polyurethane (PU) resin and to produce a positive imprint (shim) which was used in replication of the original patter by 
Roll-to-Roll Nanoimprinting (see Figure S2, ESI). 
 
For structural support, a polyester fabric sheet (Boyes UK, 
dimensions 65×30×0.1 cm) was added on top of the PDMS layer 
and the composite was allowed to cure at 25 C for 48 h. The 
cured PDMS cast of the CA15 microbeads layer was peeled off 
the glass surface and washed using warm aqueous solutions of 
detergent, ethanol and deionized water in sequence, followed 
by drying under air stream. The negative PDMS imprint (Figure 
3A,B) was then replicated further onto a polyethylene 
terephthalate (PET) foil with a pre-deposited layer of photo-
curable PU-acrylic resin (supplied from Joanneum Research 
FmbH, Graz, Austria). 
Surface modification of CA15 particle imprints  
The negative CA15 microbeads imprints on PET foil were cut in 
different lengths (2, 4, 8 and 12 cm) x 8 mm and were further surface 
functionalised to incur a weak attraction between target HL60 cells 
and the imprint. The particle imprint samples were first treated with 
oxygen plasma (Harrick Plasma PDC 32G) at 147 Pa, using an RF 
power of 16 W for 4 min. The oxygen plasma treated CA15 imprint 
samples were further incubated for 15 minutes with aqueous 
solutions of the cationic polyelectrolyte branched polyethylene 
imine (bPEI, Polysciences Inc) with different concentrations (0.01%, 
0.015%, 0.02%, 0.025%, 0.03%, 1% and 2% (w/w)). Further, they 
were rinsed with deionised water and air-dried before being 
integrated in the PDMS-based flow-through chip (Figure 4A,B) in 
order to test the CA15 microbeads imprint selectivity towards HL60 
cells in a mixture with PBMCs and HL60 cells. Additional treatment of 
the imprint and the whole chamber and tubing with solutions of 
Poloxamer 407 (Sigma Aldrich) was applied, with a range of POL407 
concentrations of 0.25%, 0.5%, 1%, 2% or 3% (w/w) in deionised 
water which were loaded in the PDMS-based chip after the bPEI-
treated particle imprint was integrated in the chip. The imprint was 
incubated with the POL407 solution for 30 min and finally washed by 
flushing with 10 mL of Phosphate Buffered Saline (PBS, Corning) at a 
flowrate of 219 mL/hr using a syringe pump (World Precision 
Instruments SP100i Syringe Pump). Tapping mode atomic force 
microscopy was carried out using a Dimension Edge (Bruker) with 
TESPA-V2 probes (Bruker). A scan rate of 0.1 Hz was used with 1024 
or 512 lines for a 50 µm scan range (Figure 3C-3D). 
Flow-through imprint device 
A Phosphate Buffer solution at 5 mM was prepared by adding 
0.78 g of sodium dihydrogen orthophosphate dihydrate (Fisher 
Chemicals) in 1 L of deionised water. The pH was adjusted to 3 
using orthophosphoric acid (Fisher Chemicals). The solution was 
heated at 50°C and 1 g of hydroxypropyl methylcellulose 
(HPMC) (sourced from Dow Chemical Company) was added 
slowly to the solution in order to obtain a solution of hydroxyl 
HPMC at 0.1% (w/v). Sylgard 184 elastomer (10:1 elastomer: 
accelerator, Dow Corning) was mixed thoroughly and degassed 
by centrifugation (Sorvall Biofuge Primo, Thermofisher 
Scientific) at 5000 g for 10 min. 3 mL of the HPMC solution was 
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Figure 3 SEM images of typical negative PDMS imprints of a layer of 15 m PMMA microbeads (Spheromers CA15) deposited on a glass slides as suspension. 
The scale bars represent (A) 100 µm and (B) 35 µm, respectively. (C-D) Atomic force microscope images of the CA15 particle imprints with different 
perspectives.  
 
It was rinsed with water and air dried. 25 mL of PDMS-hardener 
10:1 mixture was poured over glass substrates (5×50×1mm) 
with the microbeads layer, immobilised on the glass surface, 
and left to cure at 40°C for 24 h.  The PDMS was removed from 
the glass surface in order to yield identical channels on PDMS 
substrates. The microscope slide (ThermoScientific) and PDMS 
channel was treated with Oxygen Plasma (1100 mTorr, 32 W) 
for 2 min. The prepared microbeads imprint was placed over the 
channel aperture and the glass slide used to enclose the system 
(Figure 4). The device was clamped together and in a drying 
oven at 40°C for 30 min. Inlets and outlets were added by 
puncturing the PDMS and feeding with PTFE tubing (~ 0.5 mm 
diameter). 
Cell retention tests, staining and counting  
HL60 cells (sourced from Public Health England) were cultured 
aseptically in a mixture of 80 mL of Roswell Park Memorial 
Institute Medium (RPMI) 1640 (Gibco), mixed with 10 mL foetal 
bovine serum (Gibco), 5 mL penicillin and 5 mL streptomycin 
solutions (Lonza) at 37°C with 5% CO2. PBMCs were obtained 
from anonymous apparently healthy donors via the NHS blood 
transfusion service (under IRAS 214660 with REC ethical 
approval 16/LO/1948) and stored in liquid nitrogen prior to use. 
PBMCs are composed of monocyte and lymphocyte populations 
and the shape and size are generally accepted to be the same 
to a large degree, flow cytometry can highlight the cell 
populations without the need for additional staining to 
differentiate between monocytes and lymphocytes. The cells 
were slowly defrosted and washed 3 times in PBS. Removal of 
platelet contamination was achieved by triple centrifugation at 
120g for 10 min and resuspension in PBS. HL60 cells surfaces 
were fluorescently tagged by dropwise addition of 100 µL of 
0.025 wt% 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
N(carboxy-fluorescein) in ethanol to 2 mL of the stock HL60 cell 
suspension (1 × 106 cells/mL). PBMCs were treated via a similar 
method using 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-
N (Lissamine rhodamine B sulphonyl) (ammonium salt). The 
cells were washed twice separately using centrifugation (VWR, 
Mega Star 3.0R) at 400g for 5 min. The supernatant was 
removed and the cells were redispersed in deionised water. The 
cells were counted using an Improved Neubauer 
haemocytometer observed under the microscope. An Olympus 
BX51 fluorescence microscope coupled with a mercury lamp 
excitation source and DP70 camera (Olympus) with 
ImageProPlus software was used to acquire images of the 
captured cell populations retained on the CA15 imprint. 
Mixed cell sample preparation 
The desired amount of cells was taken from the master stock 
suspensions of PBMC and HL60 cells and transferred into two tubes 
(Eppendorf) in order to have a (HL60/PBMC) cell ratio of 25%/75% or 
10%/90%, respectively measured by number of cells.   
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Figure 4 (A) Schematic and (B) top side view of the actual particle imprint (of 
length 4 cm and width 6 mm) attached on a microscope slide with PDMS 
channelled casing with input and output channels. Scale bar is 1 cm. (C) 
Photographs showing the setup used for the static experiment using the 
syringe pump the cell loaded chip and the collected effluent. 
 
The ratios were chosen to mimic in vivo blast loads in AML 
where diagnosis is made at a blast proportion of 20%.31 The 
same ratio of (HL60/PBMC) cells was loaded into the fluidic 
chips of different imprint lengths. The total number of cells was 
calculated to be enough in order to saturate the smallest 
imprint (6.54  105 cells for the 2 cm chip, 1.31106 cells for the 
4 cm chip). PBS buffer was used to top up the total volume of 
the cell suspension to 1 mL. The suspensions were centrifuged 
at 400g for 6 min (with Minispin Plus Eppendorf centrifuge). The 
supernatant was then removed leaving the separated cells in 
the tube. PBS buffer was added to the PBMC tube (2 cm: 50 µL, 
4 cm: 100 µL, 8 cm: 200 µL and 12 cm: 300 µL), mixed with the 
cells and then with the HL60 cell suspension at the desired 
ratios (see below). The centrifuge tubes were sonicated using 
an ultrasonic bath for 5 min to prevent any cell aggregation. The 
prepared mixed cell suspension of the desired cell ratio was 
injected into the fluidic imprint chip and allowed to be settle on 
the imprint for 30 min. 10 mL of PBS was eluted over the particle 
imprint at different flowrates (50 mL/hr, 126 mL/hr or 219 
mL/hr) using a syringe pump (see Figure 4C). The CA15 particle 
imprint samples with the residual cells were analysed by bright 
field and fluorescence microscopy by taking images before and 
after flushing of the chip. The HL60 and PBMC cells on the 
imprint were counted using the ImageJ software using the 
macro script described in ESI. In the case of multiple seeding of 
the imprint with the HL60/PBMC cell mixture, the cells solution 
was added to the chip after the flushing step with PBS without 
removing the retained cells from the previous run. Cell viability 
was not determined throughout the tests as the latter are time 
consuming and it is very challenging to keep every batch of cells 
with the same viability. It was not possible to test viability by 
this method as the cells were already fixed stained for 
recognition purposes with dyes that would be detected with the 
same fluorescence emission. However, in principle it could be 
tested using an Annexin V staining procedure prior to flow 
cytometry analysis. Retention of HL60 cells was assessed by 
taking images (n=10) with bright field and fluorescence 
microscopy at various sites across the bioimprint. Cells were 
enumerated via the automatic method using images collected 
using FITC and TRITC in order to separately assess each cell type 
collected at each site. Each experiments was reproduced upto 3 
times and the standard deviation calculated from these results. 
Results and Discussion 
The EDX results presented in Figure S8 (ESI) clearly show that 
there is nitrogen present on the surface of the CA15 negative 
particle imprints after the treatment with 0.015 wt% bPEI and 
0.03 wt% bPEI. In comparison, the non-treated CA15 particle 
imprint sample showed has no nitrogen. Note that the nitrogen 
content on the surface increases with the increase of the bPEI 
concentration. We characterised the average diameter of the CA15 
imprint cavities which were determined to be 12.9 ± 0.9 m (Figure 
S3 and Table S1, ESI). Note that this value does not correspond to the 
equatorial diameter of the templated CA15 particles which is 14.5  
0.4 m. The reason being that the glucose layer filled the voids of the 
CA15 layer and obstructed the replicating resin to avoid formation of 
“necks” in the imprinted particles which would make impossible for 
a cell of the same radius of curvature to freely fit in. The average 
diameters of the HL60 cells and the PBMCs are 13.1 m and 9.2 m, 
respectively. This substantial difference between the radii of 
curvature of the malignant and the health white blood cells and the 
close match of the former to the CA15 microbeads imprint makes 
possible to selectively retain them on the imprint.  
HL60 selectivity optimisation  
To assess the CA15 imprint selectivity towards HL60, different 
parameters such as flowrate, the pre-treatment of the imprint 
with oxygen plasma, the bPEI and POL407 solution 
concentration were investigated. The aim was to improve the 
selectivity of the CA15 microbeads imprint towards the HL60 
blood cancer cells and to allow the PBMCs to pass through the 
imprint. Oxygen plasma treatment was firstly found to 
positively impact cell selection with 38% selectivity observed 
after such treatment but only 25% selectivity with a non-treated 
imprint (ESI, Figure S4A). This is explained with the formation of 
additional negatively charged carboxyl groups (-COO-) on the 
imprint surface after the oxygen plasma treatment which serve 
as better anchoring points of the cationic polyelectrolyte (bPEI). 
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Figure 5. The influence on cell percentage decrease (due to cell capture) and cell selectivity of (A,B) Flow rate, (C,D) bPEI concentration on the imprint, and 
(E,F) POL407 concentration on the imprint after being passed through a 4cm oxygen plasma treated PMMA imprint with 0.015 wt% bPEI, at a flow rate of 
218.9 mL/h. Data were expressed as average values ± standard deviations of the mean. P-values of less than 0.05 were considered significant.  *P <0.05, **P 
<0.01, ***P <0.001. All Unpaired two-tailed t-tests were performed in GraphPad v7.0.4. Numeric data are given in Tables S2-S7 (ESI).  
 
Therefore, all further experiments were carried out with oxygen 
plasma treated imprints. The length of the chip was then 
investigated and it was observed that imprints over 4 cm in 
length captured more cells proportionately, however at the 
expense of lower selectivity towards HL60 (Figure S4B, ESI). As 
it may be expected, the higher flowrate was associated with a 
lower retention of cells on the imprint. We found that the 
selectivity towards HL60 cells was optimal with a flowrate of 
219 mL/hr at this treatment of the imprint. The particle imprint 
had an average selectivity of 43% in HL60 at 219 mL/hr after 
flushing but only 30% at a flowrate of 50 mL/hr. These results 
enabled us to select the flowrate of 219 ml/hr as the optimal for 
losing less HL60 and more PBMC from the imprint (Figure 5A,B). 
Different concentrations of bPEI (between 0.01 wt% and 0.03 
wt%) were tested as per-treatment of the imprint in order to 
explore the effect of this cationic polymer on the HL60 cell 
selectivity of the imprint. This positively charged polymer 
adheres to the particle imprint and as a result increases the 
electrostatic interaction between the cells and the particle 
imprint surface. This effect is shown in terms of percentage of 
decrease of HL60 in Figure 5C: at 0.015 wt% bPEI treatment, 
90% of the PBMCs were released from the imprint whereas at 
0.03 wt% bPEI, only 40% were lost because they show higher 
affinity for binding with the positively charged imprint surface.  
In the terms of HL60 selectivity, 0.015 wt% bPEI treatment 
turned out to be the optimal concentration as evident from 
Figure 5D. In the others cases, the HL60 selectivity remains the 
same before and after flushing. In others cases, the selectivity 
remained the same before and after flushing. For optimisation 
of the concentration of the POL407 treatment of the imprint, 
different concentrations (between 0% and 3 wt%) of POL407 
were used to evaluate the effect on the particle imprint in terms 
of cell capture and selectivity for HL60 (Figures 5E-F). 
Selectivity for HL60 cells was achieved at POL407 
concentrations above 0.5 wt%. The POL407 prevents very 
strong adhesions between the cells and the imprint and 
therefore improve the cell selectivity. Thus, predominantly cells 
that fit tightly into the imprint cavities will be retained as the 
interaction force of the cell with the imprint is proportional to 
the contact surface area. For PBMCs, which are much smaller 
than the imprint cavities, the contact area is very small (point 
contact) which makes them loosely bound and easy to flush out, 
which allows HL60 selectivity with respect to the PBMCs. At 0 
wt% POL407 (no passivation), the particle imprint shows no 
selectivity between HL60 cells and the PBMCs: the percentage 
decrease is the same for both type of cells (35%) and the ratio 
between HL60 cells and PBMCs did not change (28%/72%) as 
evident from Figures 5E and 5F. This is explained with the 
indiscriminate strong attraction between the bPEI-treated 
imprint and the negatively charged cells. Above 0.25 wt% 
POL407 treatment, the particle imprint became selective for the 
HL60 cells. Our results show that above 0.5 wt% POL407, the 
particle imprint had been saturated with POL407 as the 
percentage decrease for the two types of cells and the 
selectivity were similar between 0.5 wt% and 3 wt%.  
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Figure 6. Cell retention on imprint as a factor of the cell seeding density and PEI concentration (A). Imprint used was 4 cm in length, coated with 3% POL407 
and (B) preferential capture of HL60 against human PBMC on 4 cm PMMA microbeads imprint, oxygen plasma treated and coated with 0.015 wt% bPEI, 3 wt% 
POL407. The flushing flow rate was of 218.9 ml/h. 
 
The particle imprint surface appeared to have become 
saturated with the highest cell concentration when pre-treated 
with 1% bPEI and 3% POL 407 (Figure 5). The cell retention was 
shown to be proportional to both the seeding cell ratio and the 
bPEI concentration. Higher bPEI concentrations, whilst retaining 
more HL60 to the imprint (Figure 6A) had the effect of loss of 
selectivity (Figure 5D) and therefore also increased PBMC 
retention. The optimal bPEI concentration was determined to 
be 0.015% (Figure 5C-D). 
Finally, the cell retention of PBMCs and HL60 was determined 
(Figure 6B) with the optimised parameters. The proportion of 
retained cells was increased with increasing of the cell seeding 
concentrations for both cell types, however, this effect was far 
more pronounced for HL60 suggesting a specificity for HL60 
over PBMCs was achieved (Figure 6B). We also conducted 
experiments with multiple seeding of the imprint up to four 
times on the chip to check the retention of HL60 cells on the 
imprint and its selectivity towards HL60 from HL60/PBMC 
mixture. According to Figure S7A (ESI), the percentage decrease 
of PBMC and HL60 follow a trend. These percentages decrease 
with the number of seeding up to a certain value. At this 
moment, the imprint becomes mostly saturated with HL60 cells. 
The percentage decrease at the 3rd and the 4th seeding are 
similar. This result can also be observed in Figure S7B, where 
the selectivity of the imprint for the HL60 cells was increasing 
until the 3rd seeding and then stagnates. The HL60 cell selection 
parameters were optimised to achieve blood tumour cell (HL60) 
specificity over healthy PBMCs. The experiments showed that 
the higher the flushing flowrate, the less amount of cells are 
retained on the imprint. However, it also indicated that the 
imprint becomes more selective with respect to HL60 cells 
when the flowrate is increased. The positively charged 
polyelectrolyte bPEI increases the electrostatic interaction 
between the cells and the imprint, hence the higher the 
concentration of the bPEI, the more the cells remain on the 
imprint. The passivating polymer, POL407 was used to weaken 
the cell adhesion and reduce non-specific binding of PBMCs 
therefore improving selectivity. Selectivity increased with 
increasing POL407 concentration up to a threshold of 0.5 wt%. 
Due to the smooth, spherical nature of the particles, relatively 
little asperity is observed with the CA15 particle imprint cavities 
as seen with cell imprints. Interactions dependent on the 
extracellular features are not seen with particle imprints and 
retention is dependent only on size matching between the 
targeted cells and the imprint. The optimal parameters for HL60 
selective capture from the CA15 PMMA microbeads imprint 
were the following, flowrate: 219 mL/hr and imprint treatment 
with oxygen plasma, 0.015 wt% bPEI and 3 wt% POL407 from a 
ratio of 25%/75% between the HL60 cells and the PBMCs. 
Particle imprints are cheaper and easier to mass produce than 
cell bioimprints which we have previously demonstrated to also 
be selective for circulating tumour cells.29 The ease of 
production and functionalisation of particle imprints as 
described here, offer an advantage over bioimprinting however 
selectivity and retention rates were lower here suggesting a 
compromise between possible universal usage of a particle 
imprint versus increased selectivity and retention of a 
personalised bioimprint.  
ARTICLE Materials Chemistry Frontiers 
8 | Mater. Chem. Front. , 2019, 00, 1-3 This journal is © The Royal Society of Chemistry 2019 
 
 
Particle imprints, however, have less surface targets compared 
to whole cell or molecule imprints where relatively small 
macromolecules such as polysaccharides, enzymes, aptamers, 
DNA sequences, antibodies as well as whole mammalian cells 
can also be targeted.32-38 The methodology described here 
could be adapted for a range of purposes such as described here 
for capture but also for cell interrogation, for example response 
to drug treatments on an individualised basis. Depletion of 
blood cancer cells from healthy cells could result in improved 
outcomes for patients.39  
Conclusions 
Here we developed an alternative and inexpensive way to 
remove blood cancer cells from a mixture with peripheral blood 
mononuclear cells by using particle imprints. We identified 
microbeads of closely matching size distribution to the blood 
cancer cells. A layer of monodisperse CA15 PMMA microbeads 
of an average diameter of ~15 m was produced and replicated 
on a large scale by PDMS and UV curable PU resin followed by 
copying of the produced master positive replica with Roll-to-
Roll Nanoimprinting lithography to fabricate negative polymeric 
replicas of the original layer of microbeads. After suitable 
surface functionalisation of the imprint we carried out 
experiments with mixtures of HL60 (blood cancer cells) and 
healthy PBMCs to explore the selectivity of the imprint towards 
the blood cancer cells. The imprint was functionalised with 
oxygen plasma treatment, cationic polyelectrolyte and 
passivation with Poloxamer 407 polymer. Our method worked 
very well based on the large size difference between the HL60 
and the PBMC. The HL60 cells closely fit in the imprint cavities 
and maximise their contact area with the imprint, while the 
PBMC have only a point contact and can be easily flushed out, 
leaving HL60 cell trapped on the imprint.  
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